GLI2 and chronic myelogenous leukemia, BCR-ABL1 positive: Studies have shown that glasdegib abrogates leukemia-initiation potential and leukemia stem cell dormancy in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) cells, most likely due to downstream GLI2 inhibition [101,102].